ReproCELL Incorporated [4978.T]
TOKYO, May 22 (Pulse News Wire) – ReproCELL Incorporated (4978.T) announced today that its subsidiary, REPROCELL USA Inc., based in Maryland, USA, has received a grant worth up to $398,535 (approximately ¥63 million) from the Maryland Stem Cell Research Fund (MSCRF). The fund, managed by TEDCO, will support the project titled "Generation of hypoimmune iPSC seed stocks for clinical applications," which runs from June 2026 to May 2027.
Under this grant, REPROCELL USA Inc. plans to combine gene-editing technology (StemEdit) with clinical-grade induced pluripotent stem cells (iPSCs) to manufacture and commercialize universal donor iPSCs. This initiative aims to reduce immune rejection risks in transplantation medicine and enhance product supply capabilities to meet the needs of pharmaceutical companies and biotech firms.
The development of universal donor iPSCs involves modifying factors causing immune rejection, such as HLA, through genetic editing techniques. This allows for cell transplantation without matching immune types, enabling large-scale pre-production and stockpiling, thereby reducing manufacturing costs and facilitating rapid delivery systems. ReproCELL Group expects this project to strengthen its position as a partner in regenerative medicine and contribute to further business expansion.
However, the company anticipates that the impact on its performance will be minor at this stage, and it will promptly disclose any significant developments in the future.
🟢 Confidence: High AI-translated content.